Table 4.

Pharmacokinetic parameters of trastuzumab and MMAF-conjugated ADCs

	AUC		Beta half-life		Clearance rate
	h·µg/mL	% vs. trastuzumab	h	% vs. trastuzumab	mL/h/kg
Trastuzumab	6964.9	100%	115.7	100%	0.37
T-N-F (T)	6795.7	98%	122.1	106%	0.37
T-N-F (C)	6813.2	98%	118.3	102%	0.38
T-C-F (T)	5933.5	85%	111.6	96%	0.43
T-C-F (C)	4315.4	62%	84.6	73%	0.60
T-K-F (T)	4324.3	62%	65.1	56%	0.64
T-K-F (C)	3718.7	54%	53.2	46%	0.69

ADCs: antibody–drug conjugates, AUC: area under the curve, T-N-F: trastuzumab-monomethyl auristatin F (MMAF) conjugate synthesized via NTERM conjugation, (T): total antibody concentration, (C): conjugate antibody concentration, T-C-F: trastuzumab-MMAF conjugate synthesized via thiol conjugation, T-K-F: trastuzumab-MMAF conjugate synthesized via lysine conjugation.